Michael Byrnes
Director of Finance/CFO presso EFFECTOR THERAPEUTICS, INC.
Patrimonio netto: 24 895 $ in data 31/03/2024
Relazioni attive
Nome | Sesso | Età | Società collegate | Collaborazione |
---|---|---|---|---|
Christopher Ehrlich | M | 54 | 3 anni | |
Stephen Worland | M | 66 | 12 anni | |
Brian Atwood | M | 71 | 3 anni | |
Brian Gallagher | M | 54 | 4 anni | |
Kristen Harrington-Smith | F | 51 | 2 anni | |
Daniel Corey | M | 44 | 3 anni | |
Elizabeth Bhatt | F | 56 | 3 anni | |
Lindsey Rolfe | M | 56 | - | |
Barbara Klencke | M | 66 | 3 anni | |
Charles Carter | M | 57 | - | |
Kathy LaPorte | F | 62 | 3 anni | |
Robyn Rapaport | F | 31 | - | |
Jennifer Doudna | M | 60 | - | |
Mayank J. Gandhi | M | 47 | 2 anni | |
Caroline Loewy | F | 58 | 1 anni | |
Mark Densel | M | - | 6 anni | |
Michael Hodges | M | - | - | |
Douglas Warner | M | 52 | 2 anni |
Grafico relazionale
Relazione in diverse aziende
Relazioni precedenti
Nome | Sesso | Età | Società collegate | Collaborazione |
---|---|---|---|---|
Isaac Stein | M | 77 |
Maxygen, Inc.
Maxygen, Inc. Miscellaneous Commercial ServicesCommercial Services Maxygen, Inc. is a biotechnology company. It is focused on the potential further development of its MAXY-G34 product, a next-generation pegylated, granulocyte colony stimulating factor, G-CSF, for the treatment of chemotherapy induced neutropenia and acute radiation syndrome. G-CSF is a natural protein that functions by stimulating the body's bone marrow to produce more white blood cells. The company was founded on May 7, 1996 and is headquartered in San Mateo, CA. | 17 anni |
John Orwin | M | 59 | 4 anni | |
James Sulat | M | 73 |
Maxygen, Inc.
Maxygen, Inc. Miscellaneous Commercial ServicesCommercial Services Maxygen, Inc. is a biotechnology company. It is focused on the potential further development of its MAXY-G34 product, a next-generation pegylated, granulocyte colony stimulating factor, G-CSF, for the treatment of chemotherapy induced neutropenia and acute radiation syndrome. G-CSF is a natural protein that functions by stimulating the body's bone marrow to produce more white blood cells. The company was founded on May 7, 1996 and is headquartered in San Mateo, CA. | 10 anni |
Gordon Ringold | M | 73 |
Maxygen, Inc.
Maxygen, Inc. Miscellaneous Commercial ServicesCommercial Services Maxygen, Inc. is a biotechnology company. It is focused on the potential further development of its MAXY-G34 product, a next-generation pegylated, granulocyte colony stimulating factor, G-CSF, for the treatment of chemotherapy induced neutropenia and acute radiation syndrome. G-CSF is a natural protein that functions by stimulating the body's bone marrow to produce more white blood cells. The company was founded on May 7, 1996 and is headquartered in San Mateo, CA. | 16 anni |
Linda Grais | M | 68 | 9 anni | |
Sharon Tetlow | F | 64 | - | |
Alana McNulty | F | 61 | 10 anni | |
Larry Lasky | M | 73 | - | |
Jean-Paul Castaigne | M | 79 | 11 anni | |
Willard Dere | M | 70 | 1 anni | |
Bradford Goodwin | M | 69 | 4 anni | |
Kenneth Lee | M | 76 |
Maxygen, Inc.
Maxygen, Inc. Miscellaneous Commercial ServicesCommercial Services Maxygen, Inc. is a biotechnology company. It is focused on the potential further development of its MAXY-G34 product, a next-generation pegylated, granulocyte colony stimulating factor, G-CSF, for the treatment of chemotherapy induced neutropenia and acute radiation syndrome. G-CSF is a natural protein that functions by stimulating the body's bone marrow to produce more white blood cells. The company was founded on May 7, 1996 and is headquartered in San Mateo, CA. | 4 anni |
Louis Lange | M | 72 |
Maxygen, Inc.
Maxygen, Inc. Miscellaneous Commercial ServicesCommercial Services Maxygen, Inc. is a biotechnology company. It is focused on the potential further development of its MAXY-G34 product, a next-generation pegylated, granulocyte colony stimulating factor, G-CSF, for the treatment of chemotherapy induced neutropenia and acute radiation syndrome. G-CSF is a natural protein that functions by stimulating the body's bone marrow to produce more white blood cells. The company was founded on May 7, 1996 and is headquartered in San Mateo, CA. | 8 anni |
John Smither | M | 71 | 2 anni | |
Michael Powell | M | 69 | 4 anni | |
Simba Gill | M | 60 |
Maxygen, Inc.
Maxygen, Inc. Miscellaneous Commercial ServicesCommercial Services Maxygen, Inc. is a biotechnology company. It is focused on the potential further development of its MAXY-G34 product, a next-generation pegylated, granulocyte colony stimulating factor, G-CSF, for the treatment of chemotherapy induced neutropenia and acute radiation syndrome. G-CSF is a natural protein that functions by stimulating the body's bone marrow to produce more white blood cells. The company was founded on May 7, 1996 and is headquartered in San Mateo, CA. | 16 anni |
Ernest Mario | M | 85 |
Maxygen, Inc.
Maxygen, Inc. Miscellaneous Commercial ServicesCommercial Services Maxygen, Inc. is a biotechnology company. It is focused on the potential further development of its MAXY-G34 product, a next-generation pegylated, granulocyte colony stimulating factor, G-CSF, for the treatment of chemotherapy induced neutropenia and acute radiation syndrome. G-CSF is a natural protein that functions by stimulating the body's bone marrow to produce more white blood cells. The company was founded on May 7, 1996 and is headquartered in San Mateo, CA. | 12 anni |
John M. Borkholder | M | 55 |
Maxygen, Inc.
Maxygen, Inc. Miscellaneous Commercial ServicesCommercial Services Maxygen, Inc. is a biotechnology company. It is focused on the potential further development of its MAXY-G34 product, a next-generation pegylated, granulocyte colony stimulating factor, G-CSF, for the treatment of chemotherapy induced neutropenia and acute radiation syndrome. G-CSF is a natural protein that functions by stimulating the body's bone marrow to produce more white blood cells. The company was founded on May 7, 1996 and is headquartered in San Mateo, CA. | 8 anni |
Jon Root | M | 64 | 1 anni | |
Lars Ekman | M | 74 | 6 anni | |
Linda L. Schock | F | - | - | |
Bosko Djordjevic | M | 70 |
Lipid Sciences, Inc.
Lipid Sciences, Inc. Miscellaneous Commercial ServicesCommercial Services Lipid Sciences, Inc. is a biotechnology company that is engaged in research and development of products and processes intended to treat major medical indications such as cardiovascular disease and viral infections in which lipids or fat components, play a key role. The company is focused on applications of technologies in two main areas: cardiovascular disease, using the HDL Therapy platform and viral infections, using the Viral Immunotherapy platform. HDL Therapy focuses on developing treatments for the reversal of atherosclerosis, which is the leading cause of heart attacks, strokes and peripheral vascular disease. It was formerly known as NZ Corp. The company was founded in 1908 and is headquartered in Pleasanton, CA. | 4 anni |
Adriann Poat | F | - |
Maxygen, Inc.
Maxygen, Inc. Miscellaneous Commercial ServicesCommercial Services Maxygen, Inc. is a biotechnology company. It is focused on the potential further development of its MAXY-G34 product, a next-generation pegylated, granulocyte colony stimulating factor, G-CSF, for the treatment of chemotherapy induced neutropenia and acute radiation syndrome. G-CSF is a natural protein that functions by stimulating the body's bone marrow to produce more white blood cells. The company was founded on May 7, 1996 and is headquartered in San Mateo, CA. | - |
Rajiv Patni | M | 55 | 1 anni | |
Renu Jain | M | - | - | |
Stan Bukofzer | M | 67 | 2 anni | |
Amy Potthoff | F | - | 1 anni | |
Mark Coffin | M | - | 2 anni | |
John E. Crawford | M | 69 |
Lipid Sciences, Inc.
Lipid Sciences, Inc. Miscellaneous Commercial ServicesCommercial Services Lipid Sciences, Inc. is a biotechnology company that is engaged in research and development of products and processes intended to treat major medical indications such as cardiovascular disease and viral infections in which lipids or fat components, play a key role. The company is focused on applications of technologies in two main areas: cardiovascular disease, using the HDL Therapy platform and viral infections, using the Viral Immunotherapy platform. HDL Therapy focuses on developing treatments for the reversal of atherosclerosis, which is the leading cause of heart attacks, strokes and peripheral vascular disease. It was formerly known as NZ Corp. The company was founded in 1908 and is headquartered in Pleasanton, CA. | 2 anni |
Amy Pernell Cavers | F | - | 1 anni | |
Timothy Arendt | M | 59 | - | |
Keith Lenden | M | - |
Maxygen, Inc.
Maxygen, Inc. Miscellaneous Commercial ServicesCommercial Services Maxygen, Inc. is a biotechnology company. It is focused on the potential further development of its MAXY-G34 product, a next-generation pegylated, granulocyte colony stimulating factor, G-CSF, for the treatment of chemotherapy induced neutropenia and acute radiation syndrome. G-CSF is a natural protein that functions by stimulating the body's bone marrow to produce more white blood cells. The company was founded on May 7, 1996 and is headquartered in San Mateo, CA. | - |
Jan Johansson | M | - |
Lipid Sciences, Inc.
Lipid Sciences, Inc. Miscellaneous Commercial ServicesCommercial Services Lipid Sciences, Inc. is a biotechnology company that is engaged in research and development of products and processes intended to treat major medical indications such as cardiovascular disease and viral infections in which lipids or fat components, play a key role. The company is focused on applications of technologies in two main areas: cardiovascular disease, using the HDL Therapy platform and viral infections, using the Viral Immunotherapy platform. HDL Therapy focuses on developing treatments for the reversal of atherosclerosis, which is the leading cause of heart attacks, strokes and peripheral vascular disease. It was formerly known as NZ Corp. The company was founded in 1908 and is headquartered in Pleasanton, CA. | 2 anni |
Gaurav Aggarwal | M | 51 | 2 anni | |
Bruce Peacock | M | 72 | 2 anni | |
Stephen E. Renneckar | M | 79 |
Lipid Sciences, Inc.
Lipid Sciences, Inc. Miscellaneous Commercial ServicesCommercial Services Lipid Sciences, Inc. is a biotechnology company that is engaged in research and development of products and processes intended to treat major medical indications such as cardiovascular disease and viral infections in which lipids or fat components, play a key role. The company is focused on applications of technologies in two main areas: cardiovascular disease, using the HDL Therapy platform and viral infections, using the Viral Immunotherapy platform. HDL Therapy focuses on developing treatments for the reversal of atherosclerosis, which is the leading cause of heart attacks, strokes and peripheral vascular disease. It was formerly known as NZ Corp. The company was founded in 1908 and is headquartered in Pleasanton, CA. | 1 anni |
Susan P. Rinne | F | 72 | 5 anni | |
Russell T. Kawahata | M | - | - | |
Premal Patel | M | 54 | 1 anni |
Statistiche
Paese | Relazioni | % del totale |
---|---|---|
Stati Uniti | 51 | 89.47% |
Età delle relazioni
Attive
Scorse
Uomo
Donna
Amministratori
Dirigenti
Provenienza delle relazioni
- Borsa valori
- Insiders
- Michael Byrnes
- Contatti personali